These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 17912014

  • 1. In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoter-driven expression of the human sodium-iodide symporter.
    Chen RF, Li ZH, Pan QH, Zhou JJ, Tang QB, Yu FY, Zhou QB, Wang J, Chen JS.
    Pancreatology; 2007; 7(5-6):505-13. PubMed ID: 17912014
    [Abstract] [Full Text] [Related]

  • 2. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter.
    Dwyer RM, Bergert ER, O'connor MK, Gendler SJ, Morris JC.
    Clin Cancer Res; 2005 Feb 15; 11(4):1483-9. PubMed ID: 15746050
    [Abstract] [Full Text] [Related]

  • 3. Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors.
    Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC.
    Hum Gene Ther; 2006 Jun 15; 17(6):661-8. PubMed ID: 16776574
    [Abstract] [Full Text] [Related]

  • 4. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice.
    Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC.
    Gene Ther; 2006 Jan 15; 13(1):60-6. PubMed ID: 16121204
    [Abstract] [Full Text] [Related]

  • 5. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
    Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC.
    Cancer Res; 2003 Nov 15; 63(22):7840-4. PubMed ID: 14633711
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone.
    Willhauck MJ, Sharif-Samani B, Senekowitsch-Schmidtke R, Wunderlich N, Göke B, Morris JC, Spitzweg C.
    Breast Cancer Res Treat; 2008 May 15; 109(2):263-72. PubMed ID: 17636401
    [Abstract] [Full Text] [Related]

  • 8. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells.
    Schipper ML, Weber A, Béhé M, Göke R, Joba W, Schmidt H, Bert T, Simon B, Arnold R, Heufelder AE, Behr TM.
    Cancer Res; 2003 Mar 15; 63(6):1333-8. PubMed ID: 12649195
    [Abstract] [Full Text] [Related]

  • 9. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter.
    Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC.
    Cancer Res; 2000 Nov 15; 60(22):6526-30. PubMed ID: 11103823
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma.
    Ma XJ, Huang R, Kuang AR.
    Cancer Invest; 2009 Jul 15; 27(6):673-81. PubMed ID: 19241193
    [Abstract] [Full Text] [Related]

  • 13. Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.
    Trujillo MA, Oneal MJ, Davydova J, Bergert E, Yamamoto M, Morris JC.
    Breast Cancer Res; 2009 Jul 15; 11(4):R53. PubMed ID: 19635153
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.
    Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L, Geissler M, Senekowitsch-Schmidtke R, Göke B, Morris JC, Spitzweg C.
    Gene Ther; 2008 Feb 15; 15(3):214-23. PubMed ID: 17989705
    [Abstract] [Full Text] [Related]

  • 18. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.
    Spitzweg C, Baker CH, Bergert ER, O'Connor MK, Morris JC.
    Hum Gene Ther; 2007 Oct 15; 18(10):916-24. PubMed ID: 17931047
    [Abstract] [Full Text] [Related]

  • 19. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells.
    Kim KI, Kang JH, Chung JK, Lee YJ, Jeong JM, Lee DS, Lee MC.
    J Nucl Med; 2007 Sep 15; 48(9):1553-61. PubMed ID: 17704247
    [Abstract] [Full Text] [Related]

  • 20. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
    Hasegawa K, Pham L, O'Connor MK, Federspiel MJ, Russell SJ, Peng KW.
    Clin Cancer Res; 2006 Mar 15; 12(6):1868-75. PubMed ID: 16551872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.